Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / BPMC - Blueprint's avapritinib OK'd in Europe for type of GI tract cancer


BPMC - Blueprint's avapritinib OK'd in Europe for type of GI tract cancer

As expected, the European Commission approves Blueprint Medicines' ([[BPMC]] -0.7%) Ayvakyt (avapritinib) as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ((GIST)) harboring the platelet-derived growth factor receptor alpha ((PDGFRA)) D842V mutation.Two months ago, the advisory group CHMP adopted a positive opinion backing approval.

For further details see:

Blueprint's avapritinib OK'd in Europe for type of GI tract cancer
Stock Information

Company Name: Blueprint Medicines Corporation
Stock Symbol: BPMC
Market: NASDAQ
Website: blueprintmedicines.com

Menu

BPMC BPMC Quote BPMC Short BPMC News BPMC Articles BPMC Message Board
Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...